Opra stock

The latest appliance is purpose-built to reliably handle rising market data volumes and volatility, including the upcoming OPRA feed upgradeSt. Louis, MO— August 23rd, 2023 – Exegy, a leading provider of end-to-end, front-office trading solutions for capital markets, is announcing its next generation ticker plant, purpose-built for processing options market data. This cutting-edge platform can process the OPRA feed on a single 2U server and provides an immediate 2x latency reduction compared to the previous generation.This 6th generation ticker plant is the foundation for future latency improvements and feature updates, continuing its 15+ year history as the ideal, managed market data solution for the industry’s top brokers, trading venues, and global hedge funds.With ever-increasing options trading volumes and the new OPRA feed going live on October 9th, the ability to reliably process growing quantities of market data with consistent, low latency is critically important for the trading community. Exegy’s unique, FPGA-based, managed appliance has scalability that cannot be matched by fully software-based solutions.David Taylor, CEO of Exegy, says: “The sustained volatility in capital markets continues to drive market data volumes to new historic peaks, especially in the US equity options markets. The OPRA consolidated tape doubling its data streams and new options markets coming online imminently further increases the pressure on existing market data infrastructures.”By the end of 2022, US stock options surpassed 10 billion contracts, with single-stock and index options volumes more than doubling since 2019. Now, OPRA’s guidance states that participants should prepare for capacity of 120+ million messages per second following the expansion.Arnaud Derasse, CPO at Exegy, adds: “Trading institutions need to boost capacity regularly with scalable and resilient infrastructure to keep pace with data volumes. This is particularly true for US options trading today. Exegy’s latest generation ticker plant offers the most compact and efficient solution,

Ticker-mobile-nav#onScroll" data-controller="ticker-mobile-nav">Ratings - OPRADividend Safety?Years of consecutive dividend increase.Returns Potential?Price target upside according to sell-side analysts.Quant Recommendation - OPRARatings analysis incomplete due to data availability. Recommendations not provided.OPRA Payout History (Paid, Declared and Estimated)YearCalendar Year Payout (USD)Calendar Year Payout Growth (USD)Pay DateDeclared DateEx-dividend DatePayout Amount (USD)Qualified Dividend?Payout TypeFrequencyDays Taken For Stock Price To RecoverYield on Cost2025e--2025-01-132024-12-122025-01-06$0.4000Non-QualifiedRegularSemi Annually-2.07%2024$0.81001.250%2024-07-152024-06-112024-07-02$0.4100Non-QualifiedRegularSemi Annually-3.22%2024-01-092023-12-122024-01-02$0.4000Non-QualifiedRegularSemi Annually-3.15%2023$0.8000-2023-07-122023-06-142023-06-29$0.4000Non-QualifiedRegularSemi Annually-2.06%2023-02-092023-01-122023-01-27$0.8000Non-QualifiedUnknown--11.90%OPRA Dividend Growth CAGRYearAmount (USD)1Y (USD)3Y (USD)5Y (USD)10Y (USD)20Y (USD)2024$0.811.25%N/AN/AN/AN/A2025$0.40N/AN/AN/AN/AN/A2026N/AN/AN/AN/AN/AN/ADividend capture strategy is based on OPRA’s historical data. Past performance is no guarantee of future results.Step 1: Buy OPRA shares 1 day before the ex-dividend datePurchase Date (Estimate)N/AUpcoming Ex-Dividend DateN/AStep 2: SEll OPRA shares when price recoversAvg Price Recovery25.5 DaysSee Full HistoryNews & ResearchNewsSorry, there are no articles available for this stock.ResearchSorry, there are no articles available for this stock.Company ProfileCompany OverviewNo company description available.© 2020 Market data provided is at least 15-minutes delayed and hosted by Barchart Solutions.Information is provided ‘as is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please see disclaimer

The internet brand is bucking the headwinds in the advertising market with terrific growth. Opera Limited (OPRA 3.08%) just reported strong financial results for the third quarter, sending the stock up 5.5% as of 1:19 p.m. ET on Thursday. The company said revenue rose 20% year over year. Surging momentum led management to raise its full-year outlook.The stock had sold off over the past year, so investors didn't have high expectations heading into the quarterly update. The shares trade at a modest valuation on a price-to-earnings basis and offer attractive upside from these levels.Why investors loved Opera's earnings reportIt's not easy to find fast-growing companies in this macroeconomic environment that are reporting balanced growth in revenue and profits. Opera's advertising revenue now makes up 59% of the business. The company is leveraging its expenses to expand margins and increase earnings per share.Earnings more than doubled versus the year-ago quarter to $0.18 per share. It's great to see Opera successfully monetizing its large base of 311 million monthly active users, as indicated by a 24% year-over-year jump in average revenue per user.The gains on the top and bottom lines should support further gains for investors.Why Opera stock could have more upsideFor the full year, Opera sees revenue coming in between $394 million and $397 million, up from previous guidance of $380 million to $390 million. That represents growth of about 19% year over year. With good expense control allowing earnings to rise even faster, the stock looks like a bargain. The forward price-to-earnings ratio currently sits at a modest 15, which is a significant discount to the average stock. John Ballard has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Approach for a patient with a stage II-III ESMO EARLY (GOOD) risk category rectal cancer (cT3a/b in mid- or high rectum, N0 (or also cN1 if high), MRF clear, no EMVI). a. Upfront surgery b. Short course radiotherapy (SCRT) followed by surgery c. Long-course chemoradiotherapy (LCCRT) followed by surgery d. Total Neoadjuvant Therapy (TNT) If choosing a TNT approach, which protocol would you prefer in this case? a. PRODIGE 23 (FOLFIRINOX – LCCRT – Surgery – FOLFOX) b. RAPIDO or STELLAR (SCRT – FOLFOX or CAPOX – Surgery) c. Induction OPRA or CAO/ARO/AIO-12 (FOLFOX – LCCRT – Surgery) d. Consolidation OPRA or CAO/ARO/AIO-12 (LCCRT – FOLFOX – Surgery) Case 2 – Indicate your preferred approach for a patient with an ESMO INTERMEDIATE risk category rectal cancer (cT3a/b if low rectum, levators clear, MRF clear OR cT3a/b in mid- or high rectum, cN1-2 (not extra-nodal), no EMVI). a. Upfront surgery b. Short course radiotherapy (SCRT) followed by surgery c. Long-course chemoradiotherapy (LCCRT) followed by surgery d. Total Neoadjuvant Therapy (TNT) If choosing a TNT approach, which protocol would you prefer in this case? a. PRODIGE 23 (FOLFIRINOX – LCCRT – Surgery – FOLFOX) b. RAPIDO or STELLAR (SCRT – FOLFOX or CAPOX – Surgery) c. Induction OPRA or CAO/ARO/AIO-12 (FOLFOX – LCCRT – Surgery) d. Consolidation OPRA or CAO/ARO/AIO-12 (LCCRT – FOLFOX – Surgery) Case 3 – Indicate your preferred approach for a patient with an ESMO BAD risk category rectal cancer (cT3c/d or very low localisation, levators threatened, MRF clear OR cT3c/d mid-rectum, cN1–N2 (extra-nodal), EMVI + OR limited cT4aN0). a. Upfront surgery b. Short course radiotherapy (SCRT) followed by surgery c. Long-course chemoradiotherapy (LCCRT) followed by surgery d. Total Neoadjuvant Therapy (TNT) If choosing a TNT approach, which protocol would you prefer in this case? a. PRODIGE 23 (FOLFIRINOX – LCCRT – Surgery – FOLFOX) b. RAPIDO or STELLAR (SCRT – FOLFOX or CAPOX – Surgery) c. Induction OPRA or CAO/ARO/AIO-12 (FOLFOX – LCCRT – Surgery) d. Consolidation OPRA or CAO/ARO/AIO-12 (LCCRT – FOLFOX – Surgery) Case 4 – Indicate your preferred approach for a patient with an ESMO

Suitable model (GPT or Gemini) to handle users' queries. The company also invested in a green-energy-powered AI data cluster in Iceland, rated one of the world's top 100 supercomputers, to support our AI-focused projects. This infrastructure allows Opera to provide its user base with the latest AI advancements in a cost effective and sustainable way. To download Opera One head to this link, and to download Opera GX use this one. To download Opera for Android Beta and use Aria without an account on the go, click here. About Opera Opera is a user-centric and innovative software company focused on enabling the best possible internet browsing experience across all devices. Hundreds of millions use Opera web browsers for their unique and secure features on mobile phones and desktop computers. Founded in 1995 and headquartered in Oslo, Norway, Opera is a public company listed on the Nasdaq stock exchange under the ticker symbol OPRA. Download the Opera web browsers and access other Opera products from opera.com. Learn more about Opera at investor.opera.com.